Drug Trial Radar · NCT01011205
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
893
Actual
Start
Sep 30, 2009
Primary completion
Jan 4, 2013
Study completion Jan 4, 2013
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Nov 11, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison of 3 dosing regimens of Advagraf to determine if there is a dosing regimen which may have the potential to cause fewer kidney problems.
Conditions
- Liver Transplantation
Interventions
AdvagrafDrug
Capsule
Mycophenolate MofetilDrug
Solution for infusion
BasiliximabDrug
IV infusion
CorticosteroidsDrug
IV bolus
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glomerular filtration rate (GFR) at 24 Weeks after transplantation estimated using the MDRD4 formulaTime frame: 24 weeks
Locations
72 sites in 23 countries. Site status is shown where the registry gives one.
160
Buenos Aires, Argentina
001
Innsbruck, Austria
146
Minsk, Belarus
008
Brussels, Belgium
006
Ghent, Belgium
009
Leuven, Belgium
010
Liège, Belgium
163
São Paulo, Brazil
153
Edmonton, Canada
150
Halifax, Canada
151
London, Canada
152
Montreal, Canada
154
Vancouver, Canada
169
Bogata, Colombia
147
Prague, Czechia
026
Helsinki, Finland
041
Besançon, France
157
Bordeaux, France
043
Caen, France
031
Créteil, France
039
Lyon, France
045
Marseille, France
158
Montpelier, France
037
Nice, France
042
Paris, France
044
Paris, France
035
Paris, France
038
Strasbourg, France
033
Toulouse, France
034
Villejuif, France
056
Berlin, Germany
058
Erlangen, Germany
051
Frankfurt, Germany
055
Göttingen, Germany
057
Hanover, Germany
142
Jena, Germany
053
Kiel, Germany
054
Leipzig, Germany
Site: 156
Mainz, Germany
052
Münster, Germany
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.